Tag: atherosclerotic cardiovascular disease
Merck launches Phase 3 CORALreef program for PCSK9 inhibitor MK-0616
Pharmaceutical giant Merck has announced the initiation of its groundbreaking Phase 3 clinical program, CORALreef, focusing on MK-0616—a novel, oral proprotein convertase subtilisin/kexin type 9 ... Read More
Novartis gets Leqvio FDA approval for reducing bad cholesterol levels
Novartis has secured approval from the US Food and Drug Administration (FDA) for its small interfering RNA (siRNA) therapy Leqvio (inclisiran) for its use in ... Read More
Novo Nordisk to acquire cardio-renal disease company Corvidia Therapeutics
Novo Nordisk acquisition of Corvidia : Danish pharma company Novo Nordisk has agreed to acquire Corvidia Therapeutics from life sciences venture capital firm Sofinnova Partners ... Read More
Novartis to acquire The Medicines Company for $9.7bn with eye on inclisiran
Novartis acquisition of The Medicines Company : Swiss drugmaker Novartis signed a deal worth $9.7 billion to acquire US biopharma company The Medicines Company, as ... Read More